JZT(SZ:000989)2014-04-25 16:00Financial Performance - Revenue for Q1 2014 was CNY 304,535,159.72, an increase of 2.95% compared to CNY 295,803,905.35 in the same period last year[6] - Net profit attributable to shareholders was CNY 41,925,368.11, representing a growth of 12.79% from CNY 37,172,418.35 year-on-year[6] - Net cash flow from operating activities surged by 235.89% to CNY 42,794,438.71, up from CNY 12,740,567.95 in the previous year[6] - Basic and diluted earnings per share increased by 16.67% to CNY 0.14 from CNY 0.12 in the same period last year[6] - Total assets at the end of the reporting period were CNY 1,973,812,786.56, a rise of 4.37% from CNY 1,891,084,260.76 at the end of the previous year[6] - The company’s net assets attributable to shareholders increased by 2.72% to CNY 1,582,960,827.93 from CNY 1,541,035,459.82 at the end of the last year[6] Shareholder Information - The number of shareholders at the end of the reporting period was 34,157[10] Corporate Developments - The company’s headquarters relocated to a new office building in Changsha during the reporting period[16] - The company’s new pharmaceutical technology industrial park passed GMP certification inspections for 10 dosage forms and 14 production lines[16] - The company plans to continue working on obtaining the GMP certification certificate[16] Relocation and Compensation - The company has committed to compensating for losses due to relocation, with a total compensation amount of RMB 12 million to be paid after the completion of the move[19] - The company is currently operating on leased land, and the relocation will result in losses to the buildings on this land[19] - The company has not yet fulfilled its commitment regarding the relocation compensation, as the fulfillment date has not arrived[19]